AKT1 E17K mutant phosphorylates TSC2, inhibiting it

Stable Identifier
R-HSA-2399982
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

AKT1 E17K gain-of-function mutant is expected to phosphorylate TSC2 and inhibit it, like the wild-type AKT (Inoki et al. 2002, Manning et al. 2002), but this has not been experimentally tested.

Literature References
PubMed ID Title Journal Year
12150915 Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

Manning, BD, Tee, AR, Logsdon, MN, Blenis, J, Cantley, LC

Mol Cell 2002
12172553 TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K, Li, Y, Zhu, T, Wu, J, Guan, KL

Nat Cell Biol 2002
Participants
Participates
Catalyst Activity

protein serine/threonine kinase activity of p-T308,S473-AKT1 E17K [cytosol]

Normal reaction
Functional status

Gain of function of p-T308,S473-AKT1 E17K [cytosol]

Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!